Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Terminated 1Suspended 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

resiniferatoxin 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Pain, Intractable × Clear all
NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡